title: Early aspirin therapy may reduce hepatic artery thrombosis in liver transplantation.
abstract: BACKGROUND
  Hepatic artery thrombosis (HAT) remains among the leading causes of early graft loss after liver transplantation. Our transplant center began using universal aspirin prophylactic therapy immediately posttransplantation in 2007. The aim of this study was to determine the safety and efficacy of early aspirin therapy on clinical outcomes.
  
  
  METHODS
  This large-scale, cross-sectional analysis included all adult liver transplantations performed between 2000 and 2009. Pediatric and multiorgan transplants were excluded. Patients were grouped and compared based on whether they received early initiation of aspirin 325 mg PO daily posttransplantation.
  
  
  RESULTS
  A total of 541 adult liver transplantations occurred during the study period; 439 had complete documentation and were analyzed. Clinical outcomes show aspirin patients had similar rates of early and late HAT, but had significantly lower early HAT, defined as HAT occurring within the first 30 days posttransplant, leading to graft loss. Other clinical outcomes were similar between groups including bleeding events and wound complications.
  
  
  CONCLUSIONS
  Immediate initiation of aspirin therapy after liver transplantation may reduce the rate of HAT leading to early graft loss, without increasing bleeding or other complication rates.
authors.affiliation: Division of Transplant Surgery, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shay
authors.forename: D
authors.initials: D
authors.lastname: Taber
authors.forename: N
authors.initials: N
authors.lastname: Pilch
authors.forename: H
authors.initials: H
authors.lastname: Meadows
authors.forename: S
authors.initials: S
authors.lastname: Tischer
authors.forename: J
authors.initials: J
authors.lastname: McGillicuddy
authors.forename: C
authors.initials: C
authors.lastname: Bratton
authors.forename: P
authors.initials: P
authors.lastname: Baliga
authors.forename: K
authors.initials: K
authors.lastname: Chavin
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006085:Graft Survival; D006487:Hemostasis; D006499:Hepatic Artery / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017093:Liver Failure / Q000601:surgery; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin